5,6-Dimethoxy-14,17-dimethyl-8-oxa-2,14,17,21,23,25-hexazatetracyclo[17.6.1.13,7.022,26]heptacosa-1(25),3(27),4,6,19,22(26),23-heptaen-13-one | 1111233-13-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 5,6-Dimethoxy-14,17-dimethyl-8-oxa-2,14,17,21,23,25-hexazatetracyclo[17.6.1.13,7.022,26]heptacosa-1(25),3(27),4,6,19,22(26),23-heptaen-13-one
• CAS: 1111233-13-6
• 化学式: C₂₄H₃₂N₆O₄
• 分子量: 468.556
• InChiKey: WWPRJOWDBONIRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  34
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  105
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• PYRROLOPYRIMIDINES
  申请人：Diels Gaston Stanislas Marcella

  公开号：US20100204197A1

  公开（公告）日：2010-08-12

  The present invention relates to compounds or pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are polo-like kinase (PLKs) inhibitors useful for the treatment of disease states mediated by PLK, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumour growth, rheumatoid arthritis, restenosis and atherosclerosis.
• US8318731B2
  申请人：——

  公开号：US8318731B2

  公开（公告）日：2012-11-27